The Goldman Sachs Group Has Lowered Expectations for Novo Nordisk A/S (NYSE:NVO) Stock Price

Novo Nordisk A/S (NYSE:NVO) had its price objective dropped by investment analysts at The Goldman Sachs Group from $60.00 to $54.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 9.43% from the company’s current price.

Several other brokerages also recently weighed in on NVO. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective on the stock in a research report on Wednesday, August 13th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $56.83.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $49.35 on Friday. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $112.52. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $220.33 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The business has a 50-day simple moving average of $52.81 and a 200-day simple moving average of $59.69.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NVO. Franklin Resources Inc. lifted its stake in Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares in the last quarter. Kingstone Capital Partners Texas LLC lifted its position in shares of Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after acquiring an additional 10,001,898 shares in the last quarter. Capital International Investors boosted its stake in shares of Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the last quarter. Boston Partners acquired a new stake in shares of Novo Nordisk A/S during the third quarter valued at $310,199,000. Finally, Nuveen LLC purchased a new stake in Novo Nordisk A/S during the 1st quarter worth about $370,272,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.